Remdesivir authorized with conditions for the treatment of patients in Canada with severe COVID-19 symptoms
Posted onJuly 28, 2020 For immediate release
Tag: Clinical Trials
Information Update – Use of the drug Picato may increase the risk of skin cancer
Posted onJuly 2, 2020 For immediate release
Chloroquine and hydroxychloroquine can have serious side effects. These drugs should be used only under the supervision of a physician.
Posted onOttawa – Chloroquine and hydroxychloroquine may cause serious side effects, including serious heart rhythm problems. The risk of these side effects may increase at higher doses, or if the drugs are used in combination with other drugs, such as the antibiotic azithromycin. Patients should use these drugs only under the supervision of a physician. Health Canada is concerned that some people may be directly buying and using chloroquine and hydroxychloroquine to prevent or treat COVID-19 without a prescription.
Addiction Clinics Market Pricey, Unproven Treatments To Desperate Patients
Posted onAn amino acid infusion called NAD is not approved by the FDA to treat addiction. Yet patients with addiction can be desperate enough to try it, at prices as high as $15,000.
MDMA, Or Ecstasy, Shows Promise As A PTSD Treatment
Posted onMDMA, the psychoactive ingredient in the club drug known as molly or ecstasy, is being tested in combination with therapy as a treatment for severe trauma.
Health Canada clarifies position on Platelet Rich Plasma treatments
Posted onOTTAWA – In follow up to Health Canada’s communication on unauthorized stem cell therapies on May 15, 2019, Health Canada would like to clarify for patients and practitioners that Platelet Rich Plasma (PRP) treatments, including Platelet Rich Fibrin treatments, are not the same as cell therapies and, as a result, are not subject to Health Canada’s Policy Position Paper on Autologous Cell Therapy Products.
FDA Overlooked Red Flags In Drugmaker’s Testing of New Depression Medicine
Posted onIn March, a chemical cousin of the anesthetic and club drug ketamine was approved for the treatment of patients with intractable depression. But critics say studies presented to the FDA provided at best modest evidence it worked and did not include information about the safety of the drug, Spravato, for long-term use.